Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Oct;35(10):2144–2146. doi: 10.1128/aac.35.10.2144

Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis.

K V Clemons 1, D A Stevens 1
PMCID: PMC245343  PMID: 1759840

Abstract

Amphotericin B as a lipid complex and as a deoxycholate suspension (Fungizone) was tested against murine blastomycosis. All doses of each form prolonged survival (P less than 0.05 to 0.001). Fungizone was more effective than lipid complex at doses of 0.8 mg/kg of body weight. However, lipid complex at 12.8 mg/kg was not toxic and superior in efficacy (P less than 0.001) to 2.0 mg of Fungizone per kg (a toxic dose), and it cleared all animals of infection. Lipid complex is an effective therapy for murine blastomycosis.

Full text

PDF
2144

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ellis W. G., Sobel R. A., Nielsen S. L. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis. 1982 Aug;146(2):125–137. doi: 10.1093/infdis/146.2.125. [DOI] [PubMed] [Google Scholar]
  2. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  3. Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis. 1982 May;145(5):748–752. doi: 10.1093/infdis/145.2.748. [DOI] [PubMed] [Google Scholar]
  4. Graybill J. R., Kaster S. R. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis. 1984 Feb;129(2):292–295. [PubMed] [Google Scholar]
  5. Harvey R. P., Schmid E. S., Carrington C. C., Stevens D. A. Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis. 1978 Apr;117(4):695–703. doi: 10.1164/arrd.1978.117.4.695. [DOI] [PubMed] [Google Scholar]
  6. Hay R. J. Fluconazole. J Infect. 1990 Jul;21(1):1–6. doi: 10.1016/0163-4453(90)90508-6. [DOI] [PubMed] [Google Scholar]
  7. Hoeprich P. Amphotericin B methyl ester and leukoencephalopathy: the other side of the coin. J Infect Dis. 1982 Aug;146(2):173–176. doi: 10.1093/infdis/146.2.173. [DOI] [PubMed] [Google Scholar]
  8. Hopfer R. L., Mills K., Mehta R., Lopez-Berestein G., Fainstein V., Juliano R. L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother. 1984 Mar;25(3):387–389. doi: 10.1128/aac.25.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lawrence R. M., Hoeprich P. D. Comparison of amphotericin B and amphotericin B methyl ester: efficacy in murine coccidioidomycosis and toxicity. J Infect Dis. 1976 Feb;133(2):168–174. doi: 10.1093/infdis/133.2.168. [DOI] [PubMed] [Google Scholar]
  10. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  11. Lopez-Berestein G. Liposomes as carriers of antifungal drugs. Ann N Y Acad Sci. 1988;544:590–597. doi: 10.1111/j.1749-6632.1988.tb40459.x. [DOI] [PubMed] [Google Scholar]
  12. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  13. Shirkhoda A., Lopez-Berestein G., Holbert J. M., Luna M. A. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology. 1986 May;159(2):349–353. doi: 10.1148/radiology.159.2.3961167. [DOI] [PubMed] [Google Scholar]
  14. Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drutz D. J., Magee W. E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982 May;125(5):610–611. doi: 10.1164/arrd.1982.125.5.610. [DOI] [PubMed] [Google Scholar]
  16. Tremblay C., Barza M., Fiore C., Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1984 Aug;26(2):170–173. doi: 10.1128/aac.26.2.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tucker R. M., Hanson L. H., Brummer E., Stevens D. A. Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. Antimicrob Agents Chemother. 1989 Apr;33(4):573–575. doi: 10.1128/aac.33.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tucker R. M., Williams P. L., Arathoon E. G., Stevens D. A. Treatment of mycoses with itraconazole. Ann N Y Acad Sci. 1988;544:451–470. doi: 10.1111/j.1749-6632.1988.tb40443.x. [DOI] [PubMed] [Google Scholar]
  19. Weber R. S., Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope. 1987 Aug;97(8 Pt 1):937–941. [PubMed] [Google Scholar]
  20. Wiebe V. J., DeGregorio M. W. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev Infect Dis. 1988 Nov-Dec;10(6):1097–1101. doi: 10.1093/clinids/10.6.1097. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES